Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
LIMNW
LIMINATUS PHARMA, INC. WARRANTS
NASDAQ
$0.05
▲ UP 11.67% (0.01)

KEY STATISTICS

Market Cap$1.31 M
52w High$0.05
52w Low$0.04
Dividend Yield—
Frequency—
P/E—
Volume4
Shares Out.26.83M

COMPANY

LEADERSHIP

Chris Kim
CHIEF EXECUTIVE
Chris Kim

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 30, 2025
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
1

PRICE

$0.05 ▲ UP 11.67% (+$0.01)
$0.05$0.05$0.05$0.0510:57 AM10:57 AM10:57 AM10:57 AM10:57 AM10:57 AM10:58 AM0.05

About Liminatus Pharma, Inc. Warrants

https://liminatuspharma.com ↗

Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

INDUSTRY

Biotechnology

A PRODUCT LIMINATUS PHARMA, INC. WARRANTS IS KNOWN FOR

IBA101
IBA101

IBA101, developed by Liminatus Pharma, is a next-generation CD47-blockade antibody targeting solid tumors to enhance immune recognition and attack, serving as the company's lead immunotherapy candidate.

COMPETITORS

COMPETITOR
ALXO COMPARE
GILD COMPARE
PFE COMPARE
STTK COMPARE

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
10 PERCENT OWNER
Valetudo Therapeutics LLC
Purchase · 3.4M shares
2026-07-02
★
10 PERCENT OWNER
Valetudo Therapeutics LLC
Sale · 4.4M shares
2026-06-24
★
10 PERCENT OWNER
Ewon Comfortech Co., Ltd.
— · —
2026-06-24

SECTORS PEERS

PEERPRICE
VRAX$2.54COMPARE
BIVI$1.61COMPARE
GLMD$4.63COMPARE
MLEC$6.10COMPARE
ELAB$4.78COMPARE
PTIX$0.91COMPARE
ARTL$3.94COMPARE
XRTX$1.92COMPARE